The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

We characterized the mechanism of action of the neuregulin-non-competitive anti-HER3 therapeutic antibody 9F7-F11 that blocks the PI3K/AKT pathway, leading to cell cycle arrest and apoptosis in vitro and regression of pancreatic and breast cancer in vivo. We found that 9F7-F11 induces rapid HER3 dow...

Full description

Saved in:

Bibliographic Details
Published in:	Oncotarget Vol. 7; no. 24; pp. 37013 - 37029
Main Authors:	Le Clorennec, Christophe, Lazrek, Yassamine, Dubreuil, Olivier, Larbouret, Christel, Poul, Marie-Alix, Mondon, Philippe, Melino, Gerry, Pèlegrin, André, Chardès, Thierry
Format:	Journal Article
Language:	English
Published:	United States Impact journals 14-06-2016 Impact Journals LLC
Subjects:	Antibodies, Monoclonal Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Murine-Derived Antibodies, Monoclonal, Murine-Derived - pharmacology Antineoplastic Agents Antineoplastic Agents - pharmacology Cancer Cell Line, Tumor Down-Regulation Human health and pathology Humans Life Sciences MAP Kinase Signaling System MAP Kinase Signaling System - drug effects MAP Kinase Signaling System - physiology Mitogen-Activated Protein Kinase 8 Mitogen-Activated Protein Kinase 8 - metabolism Mitogen-Activated Protein Kinase 9 Mitogen-Activated Protein Kinase 9 - metabolism Receptor, ErbB-3 Receptor, ErbB-3 - antagonists & inhibitors Repressor Proteins Repressor Proteins - drug effects Repressor Proteins - metabolism Research Paper Ubiquitin-Protein Ligases Ubiquitin-Protein Ligases - drug effects Ubiquitin-Protein Ligases - metabolism Ubiquitination treatment ITCH/AIP4 cancer antibody HER3
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!